title: Effect of a milk formula containing probiotics on the fecal microbiota of asian infants at risk of atopic diseases.
abstract: The fecal microbiota of 37 infants with (n = 20) or without (n = 17) probiotic administration was evaluated on D 3, and at 1, 3, and 12 mo by fluorescence in situ hybridization-flow cytometry (FISH-FC), PCR, and bacteriological culture methods. They represent consecutive subjects of an ongoing double-blind, placebo-controlled trial on a probiotic formula (LGG and Bifidobacterium longum) administered during the first 6 mo of life. Despite varying composition in each baby, there was a general bacterial colonization pattern in the first year. Bifidobacteria increased markedly (p = 0.0003) with a parallel decrease in Enterobacteriaceae (p < 0.001) and Bacteroides-Prevotella (p = 0.005) populations. Eubacterium rectale-Clostridium coccoides (p < 0.001) and Atopobium (p = 0.039) groups also gradually increased. This overall pattern was unaffected by probiotic administration (p > 0.05). B. longum (p = 0.005) and Lactobacillus rhamnosus (p < 0.001) were detected more frequently in probiotic group during supplementation, but no difference after supplementation had ceased (p > 0.05). Cultured lactic acid bacteria were also more numerous in the probiotic-administered babies during treatment period (log CFU/g 8.4 versus 7.4; p = 0.035). Our results indicate that supplemented strains could be detected but did not persist in the bowel once probiotic administration had ceased.
authors.affiliation: Department of Paediatrics, National University of Singapore, Singapore 119074.
authors.forename: Ka Weng
authors.initials: KW
authors.lastname: Mah
authors.forename: Vanessa I L
authors.initials: VI
authors.lastname: Chin
authors.forename: Wen Seen
authors.initials: WS
authors.lastname: Wong
authors.forename: Christophe
authors.initials: C
authors.lastname: Lay
authors.forename: Gerald W
authors.initials: GW
authors.lastname: Tannock
authors.forename: Lynette P
authors.initials: LP
authors.lastname: Shek
authors.forename: Marion M
authors.initials: MM
authors.lastname: Aw
authors.forename: Kaw Yan
authors.initials: KY
authors.lastname: Chua
authors.forename: Hwee Bee
authors.initials: HB
authors.lastname: Wong
authors.forename: Anushia
authors.initials: A
authors.lastname: Panchalingham
authors.forename: Bee Wah
authors.initials: BW
authors.lastname: Lee
mesh_terms: D044466:Asian People; D001431:Bacteriological Techniques; D001439:Bacteroides / Q000254:growth & development; D001644:Bifidobacterium / Q000235:genetics / Q000254:growth & development; D003013:Clostridium / Q000254:growth & development; D004269:DNA, Bacterial / Q000032:analysis; D004311:Double-Blind Method; D004755:Enterobacteriaceae / Q000254:growth & development; D005051:Eubacterium / Q000254:growth & development; D005243:Feces / Q000382:microbiology*; D005260:Female; D005434:Flow Cytometry; D041981:Gastrointestinal Tract / Q000382:microbiology*; D005865:Gestational Age; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000382:microbiology*; D017404:In Situ Hybridization, Fluorescence; D007223:Infant; D041943:Infant Formula / Q000008:administration & dosage*; D007231:Infant, Newborn; D052201:Lacticaseibacillus rhamnosus / Q000235:genetics / Q000254:growth & development; D008297:Male; D016133:Polymerase Chain Reaction; D018720:Prevotella / Q000254:growth & development; D019936:Probiotics / Q000008:administration & dosage*; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors
chemical_list: D004269:DNA, Bacterial